COVID-19 Can Cause Bone Marrow Suppression
Yes, COVID-19 can cause bone marrow suppression and alterations, though the mechanisms are indirect rather than from direct viral replication in the bone marrow.
Evidence of Bone Marrow Impact
The most compelling evidence comes from autopsy studies showing significant bone marrow changes in COVID-19 patients. A 2023 study examining 28 autopsy cases demonstrated that bone marrow specimens showed left-shifted myelopoiesis (64%), increased myeloid-erythroid ratio (28%), and increased megakaryopoiesis (21%) 1. Critically, while SARS-CoV-2 was confirmed in respiratory tissues, it was not detected in bone marrow by high-sensitivity PCR, indicating the virus does not directly replicate in the hematopoietic microenvironment 1.
Key Pathological Findings
Hemophagocytosis and Macrophage Activation
The most striking finding is hemophagocytosis, observed in 54% of COVID-19 bone marrow specimens compared to 0% in controls 1. This was corroborated by another autopsy series showing hemophagocytic histiocytes in all 19 evaluable bone marrows, with HScore calculations suggesting secondary hemophagocytic lymphohistocytosis (HLH) in multiple patients 2. Indian autopsy data confirmed hemophagocytosis in 40% of cases with marked histiocyte prominence in 68.5% 3.
The erythrophagocytosis correlated directly with lower hemoglobin levels clinically 1, providing a mechanistic link between bone marrow pathology and peripheral cytopenias.
B Cell Depletion
A concerning finding is severe B cell loss in bone marrow and/or spleen in 64% of COVID-19 patients, associated with higher pulmonary SARS-CoV-2 burden and peripheral lymphocytopenia 4. This B cell depletion may impede the durability of humoral immune responses.
Immune Environment Changes
COVID-19 bone marrow showed a strong increase in CD68+ macrophages (57%) and borderline lymphocytosis (18%) 1. Plasma cell prominence was noted in 80% of cases 3, reflecting immune activation.
Mechanisms of Suppression
The bone marrow suppression occurs through indirect mechanisms rather than direct viral infection:
- Cytokine release syndrome driving inflammatory damage
- Hemophagocytic lymphohistocytosis causing consumption of blood cells
- Hypoxic environment affecting hematopoiesis
- NLRP3 inflammasome activation and Th17 cell recruitment
- Medication effects (corticosteroids and antivirals used in treatment)
- Sepsis-acquired immunodeficiency in cases with superinfection 4
Clinical Implications
Peripheral Blood Manifestations
Expect to see:
- Neutrophilic leukocytosis (common)
- Lymphopenia (very common)
- Anemia (frequent, related to hemophagocytosis)
- Thrombocytopenia (common)
- Rarely, secondary polycythemia 2
Management Considerations in Hematologic Malignancies
For patients with underlying hematologic conditions, dose-attenuated regimens and careful growth factor use should be considered to reduce myelosuppression risk and hospitalization duration 5. The guidelines emphasize avoiding periods of immunosuppression while maintaining effective disease-directed treatment [@1-4@].
Important Caveats
- The severity of bone marrow changes appears to correlate with COVID-19 disease severity
- Coinfections were present in 30% of autopsy cases, potentially contributing to findings 2
- The bone marrow changes are reactive and indirect, not from direct viral cytopathic effects
- Recovery patterns and long-term hematopoietic consequences remain under investigation
The evidence clearly establishes that COVID-19 causes bone marrow suppression through inflammatory and immune-mediated mechanisms, with hemophagocytosis being the most consistent and clinically significant finding.